JSP chooses Amneal after ceasing Lannett
Amneal Pharmaceuticals is to stake a claim in “one of the most compelling generic product markets in the United States today” by signing a 10-year licence and supply agreement with Jerome Stevens Pharmaceuticals (JSP) for levothyroxine sodium tablets, after the family-owned company opted against renewing its existing agreement with Lannett (see page 14).
You may also be interested in...
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.